Biomarker targets: lipoprotein(a) vs apolipoprotein A-I
Lipoprotein(a) (Lp(a)) is an LDL-like particle that carries apolipoprotein(a) as an additional component. [1] Apolipoprotein A-I (ApoA-I) is the major apolipoprotein associated with high-density lipoprotein (HDL). [2]
Molecular composition and what each test measures
Lp(a) quantification reflects the concentration of the Lp(a) particle in blood. [1] ApoA-I measurement reflects the concentration of the ApoA-I protein in serum, which varies with HDL biology. [2]
Clinical context for ordering
Lp(a) testing is used to assess inherited cardiovascular risk. [1] ApoA-I testing is used in some settings for cardiovascular risk evaluation and for detection of specific genetic disorders such as Tangier disease. [3]
Test units and how results are reported
Lp(a) is commonly reported in nmol/L or mg/dL, and harmonization across assays remains incomplete. [1] ApoA-I is reported as a serum concentration (example: mg/dL). [3]
Analytical challenges specific to lipoprotein(a) assays
Lp(a) measurement has assay-dependent bias because results can be influenced by apo(a) size heterogeneity and assay calibration approaches. [1] Isoform-sensitive vs isoform-insensitive assay behavior is a major driver of measurement variability across commercial methods. [4]
Analytical considerations for ApoA-I assays
ApoA-I immunoassays measure ApoA-I protein concentration using anti-ApoA-I antibodies. [3] ApoA-I quantity is not a strict 1:1 surrogate for HDL particle number because the number of ApoA-I proteins per HDL particle varies. [3]
Practical difference for interpretation
Lp(a) values are interpreted in light of Lp(a) assay standardization limits and unit conventions. [1] ApoA-I values are interpreted as HDL-associated protein levels rather than as a direct count of HDL particles. [3]